Drug lookup | Fillwise

THEOPHYLLINE ANHYDROUS

All products: general benefit

Other products in the same Health Canada class (R03DA) — coverage varies; not interchangeable

Oxtriphylline (Choledyl): general benefit

Theo ER · DIN 02360101 · 400mg · extended release tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Theo ER · DIN 02360101 Manufacturer: A A Pharma Inc.; listing date 2014-01-03 Health Canada: Marketed since 2011-06-23 · brand THEO ER · ATC R03DA04 THEOPHYLLINE · form Tablet (extended-release) · route Oral · ingredients THEOPHYLLINE 400 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.3734 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84507 · Verify on the e-Formulary ↗ (DIN 02360101)

Source record

DIN 02360101: Theo ER Raw flags: sec3=Y Item: 860000046; group id 878; item number 2118; lccId None; manufacturer id AAP Source form: SR Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $0.3735; ministry $0.3734 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02360101 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84507

Interchangeable products

Uniphyl · DIN 02014165 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02360101

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Other drugs in the same formulary class (86:00 SPASMOLYTICS) and how they are covered

Matched class: 86:00 SPASMOLYTICS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: OXTRIPHYLLINE 86:00 SPASMOLYTICS

OXTRIPHYLLINE

· 1 products · General benefit · strengths: 20mg/mL · O/L

FESOTERODINE FUMARATE

· 6 products · Limited Use, codes 290 · strengths: 4mg, 8mg · Tab

MIRABEGRON

· 5 products · Limited Use, codes 290 · strengths: 25mg, 50mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 86:00 86:12:04 Antimuscarinics

PROPIVERINE HYDROCHLORIDE

· 1 products · Limited Use, codes 530 · strengths: 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 86:12:04

Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1. INDICATIONS THEO ER (theophylline sustained release tablets) is indicated for: Symptomatic treatment of reversible bronchoconstriction associated with asthma, emphysema, chronic bronchitis and related bronchospastic disorders in patients 12 years and older. 1.1. Pediatrics Pediatrics (<12 years of age): THEO ER is not recommended for use in children under 12 years of age. 1.2. Geriatrics Geriatrics (>65 years of age): Dose Reduction may be required in elderly patients (see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS) https://pdf.hres.ca/dpd_pm/00063080.PDF PM date: September 28, 2021 Source product: THEO ER; DIN 02360101; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.